Randomised phase 2 trial of hepatic arterial chemotherapy with cisplatin and 5-FU versus sorafenib in patients with advanced unresectable hepatocellulare carcinoma
Phase 2
Recruiting
- Conditions
- unresectable advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000003917
- Lead Sponsor
- Kurume University, School od Medicine Department of Medicine, Division of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) extrahepatic metastasis 2) pregnant woman 3) drug allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time to progression therapeutic efficacy
- Secondary Outcome Measures
Name Time Method overall survival